Distinct roles of central and peripheral prostaglandin e 2 and EP subtypes in blood pressure regulation

American Journal of Hypertension

Volumn 25, Issue 10, 2012, Pages 1042-1049

  Yang, Tianxin ^a,b   Du, Yaomin ^c  

^a SUN YAT SEN UNIVERSITY   (China)

^b UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^c GUANGDONG PROVINCIAL PEOPLE'S HOSPITAL   (China)

Author keywords

blood pressure; brain; EP receptors; hypertension; kidney; mPGES 1; prostaglandin E2

Indexed keywords

PROSTAGLANDIN E RECEPTOR; PROSTAGLANDIN E2; RENIN;

BLOOD PRESSURE REGULATION; GLOMERULUS FILTRATION RATE; HEMODYNAMICS; HOMEOSTASIS; HUMAN; HYPERTENSION; KIDNEY BLOOD FLOW; KIDNEY CIRCULATION; KIDNEY ISCHEMIA; KIDNEY TUBULE; MICROCIRCULATION; NONHUMAN; PRIORITY JOURNAL; REVIEW; VASOCONSTRICTION; VASODILATATION;

ANIMALS; BLOOD PRESSURE; DINOPROSTONE; HUMANS; KIDNEY; RECEPTORS, PROSTAGLANDIN E; RECEPTORS, PROSTAGLANDIN E, EP2 SUBTYPE; RECEPTORS, PROSTAGLANDIN E, EP3 SUBTYPE; RECEPTORS, PROSTAGLANDIN E, EP4 SUBTYPE;

EID: 84866433495     PISSN: 08957061     EISSN: 19417225     Source Type: Journal    
DOI: 10.1038/ajh.2012.67     Document Type: Review

References (101)

1. Vane Jr. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nature New Biol 1971; 231:232-235.
2. Jakobsson PJ, Thorén S, Morgenstern R, Samuelsson B. Identification of human prostaglandin E synthase: a microsomal, glutathione-dependent, inducible enzyme, constituting a potential novel drug target. Proc Natl Acad Sci USA 1999; 96:7220-7225. (Pubitemid 29299642)
3. Chang HH, Meuillet EJ. Identification and development of mPGES-1 inhibitors: where we are at? Future Med Chem 2011; 3:1909-1934.
4. Chi Y, Min J, Jasmin JF, Lisanti MP, Chang YT, Schuster VL. Development of a highaffinity inhibitor of the prostaglandin transporter. J Pharmacol Exp Ther 2011; 339:633-641.
5. Jia Z, Wang H, Yang T. Mice lacking mPGES-1 are resistant to lithium-induced polyuria. Am J Physiol Renal Physiol 2009; 297:F1689-F1696.
6. Jia Z, Aoyagi T, Yang T. mPGES-1 protects against DOCA-salt hypertension via inhibition of oxidative stress or stimulation of NO/cGMP. Hypertension 2010; 55:539-546.
7. Jia Z, Guo X, Zhang H, Wang MH, Dong Z, Yang T. Microsomal prostaglandin synthase-1-derived prostaglandin E2 protects against angiotensin II-induced hypertension via inhibition of oxidative stress. Hypertension 2008; 52:952-959.
8. Jia Z, Yan G, Liu H, Wang Z, Jiang P, Shi Y. The optimization of wireless power transmission: design and realization. Int J Med Robot 2012.
9. Francois H, Facemire C, Kumar A, Audoly L, Koller B, Coffman T. Role of microsomal prostaglandin E synthase 1 in the kidney. J Am Soc Nephrol 2007; 18:1466-1475. (Pubitemid 46717513)
10. Harding P, Yang XP, He Q, Lapointe MC. Lack of microsomal prostaglandin E synthase-1 reduces cardiac function following angiotensin II infusion. Am J Physiol Heart Circ Physiol 2011; 300:H1053-H1061.
11. Facemire CS, Griffiths R, Audoly LP, Koller BH, Coffman TM. The impact of microsomal prostaglandin e synthase 1 on blood pressure is determined by genetic background. Hypertension 2010; 55:531-538.
12. Jia Z, Aoyagi T, Kohan DE, Yang T. mPGES-1 deletion impairs aldosterone escape and enhances sodium appetite. Am J Physiol Renal Physiol 2010; 299:F155-F166.
13. Jania LA, Chandrasekharan S, Backlund MG, Foley NA, Snouwaert J, Wang IM, Clark P, Audoly LP, Koller BH. Microsomal prostaglandin E synthase-2 is not essential for in vivo prostaglandin E2 biosynthesis. Prostaglandins Other Lipid Mediat 2009; 88:73-81.
14. Nakatani Y, Hokonohara Y, Kakuta S, Sudo K, Iwakura Y, Kudo I. Knockout mice lacking cPGES/p23, a constitutively expressed PGE2 synthetic enzyme, are peri-natally lethal. Biochem Biophys Res Commun 2007; 362:387-392. (Pubitemid 47332420)
15. Lovgren AK, Kovarova M, Koller BH. cPGES/p23 is required for glucocorticoid receptor function and embryonic growth but not prostaglandin E2 synthesis. Mol Cell Biol 2007; 27:4416-4430. (Pubitemid 46906565)
16. Sugimoto Y, Narumiya S. Prostaglandin E receptors. J Biol Chem 2007; 282:11613-11617. (Pubitemid 47100657)
17. Zhang Y, Guan Y, Schneider A, Brandon S, Breyer RM, Breyer MD. Characterization of murine vasopressor and vasodepressor prostaglandin E(2) receptors. Hypertension 2000; 35:1129-1134. (Pubitemid 30327269)
18. Lydford SJ, McKechnie KC, Dougall IG. Pharmacological studies on prostanoid receptors in the rabbit isolated saphenous vein: a comparison with the rabbit isolated ear artery. Br J Pharmacol 1996; 117:13-20. (Pubitemid 26030247)
19. Lawrence RA, Jones RL. Investigation of the prostaglandin E (EP-) receptor subtype mediating relaxation of the rabbit jugular vein. Br J Pharmacol 1992; 105:817-824.
20. Coleman RA, Grix SP, Head SA, Louttit JB, Mallett A, Sheldrick RL. A novel inhibitory prostanoid receptor in piglet saphenous vein. Prostaglandins 1994; 47:151-168. (Pubitemid 24089361)
21. Hristovska AM, Rasmussen LE, Hansen PB, Nielsen SS, Nüsing RM, Narumiya S, Vanhoutte P, Skøtt O, Jensen BL. Prostaglandin E2 induces vascular relaxation by E-prostanoid 4 receptor-mediated activation of endothelial nitric oxide synthase. Hypertension 2007; 50:525-530. (Pubitemid 47312239)
22. Foudi N, Kotelevets L, Louedec L, Leséche G, Henin D, Chastre E, Norel X. Vasorelaxation induced by prostaglandin E2 in human pulmonary vein: role of the EP4 receptor subtype. Br J Pharmacol 2008; 154:1631-1639.
23. Davis RJ, Murdoch CE, Ali M, Purbrick S, Ravid R, Baxter GS, Tilford N, Sheldrick RL, Clark KL, Coleman RA. EP4 prostanoid receptor-mediated vasodilatation of human middle cerebral arteries. Br J Pharmacol 2004; 141:580-585. (Pubitemid 38453250)
24. Francois H, Facemire C, Kumar A, Audoly L, Koller B, Coffman T. Role of microsomal prostaglandin E synthase 1 in the kidney. J Am Soc Nephrol 2007; 18:1466-1475. (Pubitemid 46717513)
25. Matsuda H, Hayashi K, Arakawa K, Kubota E, Honda M, Tokuyama H, Suzuki H, Yamamoto T, Kajiya F, Saruta T. Distinct modulation of superficial and juxtamedullary arterioles by prostaglandin in vivo. Hypertens Res 2002; 25:901-910. (Pubitemid 36024647)
26. Foudi N, Kotelevets L, Gomez I, Louedec L, Longrois D, Chastre E, Norel X. Differential reactivity of human mammary artery and saphenous vein to prostaglandin E(2): implication for cardiovascular grafts. Br J Pharmacol 2011; 163:826-834.
27. Kobayashi K, Murata T, Hori M, Ozaki H. Prostaglandin E2-prostanoid EP3 signal induces vascular contraction via nPKC and ROCK activation in rat mesenteric artery. Eur J Pharmacol 2011; 660:375-380.
28. Arisz L, Donker AJ, Brentjens JR, van der Hem GK. The effect of indomethacin on proteinuria and kidney function in the nephrotic syndrome. Acta Med Scand 1976; 199:121-125.
29. Walshe JJ, Brentjens JR, Costa GG, Andres GA, Venuto RC. Abdominal pain associated with IgA nephropathy. Possible mechanism. Am J Med 1984; 77:765-767. (Pubitemid 14047617)
30. Antillon M, Cominelli F, Lo S, Moran M, Somberg K, Reynolds T, Zipser RD. Effects of oral prostaglandins on indomethacin-induced renal failure in patients with cirrhosis and ascites. J Rheumatol Suppl 1990; 20:46-49. (Pubitemid 20099221)
31. Huerta C, Rodríguez LA. Incidence of ocular melanoma in the general population and in glaucoma patients. J Epidemiol Community Health 2001; 55:338-339. (Pubitemid 32336976)
32. Edwards RM. Effects of prostaglandins on vasoconstrictor action in isolated renal arterioles. Am J Physiol 1985; 248:F779-F784. (Pubitemid 16241883)
33. Imig JD, Breyer MD, Breyer RM. Contribution of prostaglandin EP(2) receptors to renal microvascular reactivity in mice. Am J Physiol Renal Physiol 2002; 283:F415-F422.
34. Mattson DL, Lu S, Nakanishi K, Papanek PE, Cowley AW Jr. Effect of chronic renal medullary nitric oxide inhibition on blood pressure. Am J Physiol 1994; 266:H1918-H1926.
35. Mattson DL, Lu S, Cowley AW Jr. Role of nitric oxide in the control of the renal medullary circulation. Clin Exp Pharmacol Physiol 1997; 24:587-590. (Pubitemid 27323193)
36. Mattson DL, Meister CJ. Renal cortical and medullary blood flow responses to L-NAME and ANG II in wild-type, nNOS null mutant, and eNOS null mutant mice. Am J Physiol Regul Integr Comp Physiol 2005; 289:R991-R997. (Pubitemid 41397046)
37. Nakanishi K, Mattson DL, Cowley AW Jr. Role of renal medullary blood flow in the development of L-NAME hypertension in rats. Am J Physiol 1995; 268:R317-R323.
38. Ye W, Zhang H, Hillas E, Kohan DE, Miller RL, Nelson RD, Honeggar M, Yang T. Expression and function of COX isoforms in renal medulla: evidence for regulation of salt sensitivity and blood pressure. Am J Physiol Renal Physiol 2006; 290:F542-F549. (Pubitemid 43725008)
39. Pallone TL. Vasoconstriction of outer medullary vasa recta by angiotensin II is modulated by prostaglandin E2. Am J Physiol 1994; 266:F850-F857.
40. Silldorff EP, Yang S, Pallone TL. Prostaglandin E2 abrogates endothelin-induced vasoconstriction in renal outer medullary descending vasa recta of the rat. J Clin Invest 1995; 95:2734-2740.
41. Chen J, Zhao M, He W, Milne GL, Howard JR, Morrow J, Hébert RL, Breyer RM, Chen J, Hao CM. Increased dietary NaCl induces renal medullary PGE2 production and natriuresis via the EP2 receptor. Am J Physiol Renal Physiol 2008; 295:F818-F825.
42. Elsner D, Müntze A, Kromer EP, Riegger GA. Prostaglandin I2 versus prostaglandin E2 in dogs with and without low cardiac output. Differential effects on renal function. Am J Hypertens 1992; 5:175-179.
43. Jones RL, Watson ML, Ungar A. A comparison of the effects of prostaglandins E2 and I2 on renal function and renin release in salt-loaded and salt-depleted anaesthetized dogs. Q J Exp Physiol 1981; 66:1-15. (Pubitemid 11014136)
44. Stokes JB, Kokko JP. Inhibition of sodium transport by prostaglandin E2 across the isolated, perfused rabbit collecting tubule. J Clin Invest 1977; 59:1099-1104. (Pubitemid 8131064)
45. Guan Y, Zhang Y, Breyer RM, Fowler B, Davis L, Hébert RL, Breyer MD. Prostaglandin E2 inhibits renal collecting duct Na+ absorption by activating the EP1 receptor. J Clin Invest 1998; 102:194-201. (Pubitemid 28323846)
46. Fine LG, Trizna W. Influence of prostaglandins on sodium transport of isolated medullary nephron segments. Am J Physiol 1977; 232:F383-F390.
47. Sakairi Y, Jacobson HR, Noland TD, Breyer MD. Luminal prostaglandin E receptors regulate salt and water transport in rabbit cortical collecting duct. Am J Physiol 1995; 269:F257-F265.
48. DiBona GF. Sympathetic nervous system and the kidney in hypertension. Curr Opin Nephrol Hypertens 2002; 11:197-200.
49. Krum H, Schlaich M, Whitbourn R, Sobotka PA, Sadowski J, Bartus K, Kapelak B, Walton A, Sievert H, Thambar S, Abraham WT, Esler M. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet 2009; 373:1275-1281.
50. Kopp UC, Cicha MZ, Smith LA, Ruohonen S, Scheinin M, Fritz N, Hökfelt T. Dietary sodium modulates the interaction between efferent and afferent renal nerve activity by altering activation of a2-adrenoceptors on renal sensory nerves. Am J Physiol Regul Integr Comp Physiol 2011; 300:R298-R310.
51. Kopp UC, Grisk O, Cicha MZ, Smith LA, Steinbach A, Schlüter T, Mähler N, Hökfelt T. Dietary sodium modulates the interaction between efferent renal sympathetic nerve activity and afferent renal nerve activity: role of endothelin. Am J Physiol Regul Integr Comp Physiol 2009; 297:R337-R351.
52. Kopp UC, Cicha MZ, Smith LA. Differential effects of endothelin on activation of renal mechanosensory nerves: stimulatory in high-sodium diet and inhibitory in low-sodium diet. Am J Physiol Regul Integr Comp Physiol 2006; 291:R1545-R1556.
53. Kopp UC, Cicha MZ, Smith LA, Ruohonen S, Scheinin M, Fritz N, Hokfelt T. Dietary sodium modulates the interaction between efferent and afferent renal nerve activity by altering activation of alpha2-adrenoceptors on renal sensory nerves. Am J Physiol Regul Integr Comp Physiol 2011; 300:R298-R310.
54. Kopp UC, Cicha MZ. PGE2 increases substance P release from renal pelvic sensory nerves via activation of N-type calcium channels. Am J Physiol 1999; 276:R1241-R1248. (Pubitemid 29249645)
55. Kopp UC, Cicha MZ, Smith LA. PGE(2) increases release of substance P from renal sensory nerves by activating the cAMP-PKA transduction cascade. Am J Physiol Regul Integr Comp Physiol 2002; 282:R1618-R1627. (Pubitemid 34664486)
56. Kondo K, Okuno T, Saruta T, Kato E. Effects of intracerebroventricular administration of prostaglandins I2, E2, F2 alpha and indomethacin on blood pressure in the rat. Prostaglandins 1979; 17:769-774. (Pubitemid 9217942)
57. Hoffman WE, Schmid PG. Cardiovascular and antidiuretic effects of central prostaglandin E2. J Physiol (Lond) 1979; 288:159-169. (Pubitemid 9146879)
58. Takahashi H, Buñag RD. Pressor responses to centrally-administered prostaglandin E2 in spontaneously hypertensive rats. Hypertension 1981; 3:426-432. (Pubitemid 11002039)
59. Okuno T, Lindheimer MD, Oparil S. Central effects of prostaglandin E2 on blood pressure and plasma renin activity in rats. Role of the sympathoadrenal system and vasopressin. Hypertension 1982; 4:809-816. (Pubitemid 13176947)
60. Feuerstein G, Adelberg SA, Kopin IJ, Jacobowitz DM. Hypothalamic sites for cardiovascular and sympathetic modulation by prostaglandin E2. Brain Res 1982; 231:335-342. (Pubitemid 12203129)
61. Westfall TC. Local regulation of adrenergic neurotransmission. Physiol Rev 1977; 57:659-728. (Pubitemid 8232524)
62. Medina P, Segarra G, Mauricio MD, Vila JM, Chuan P, Lluch S. Role of Ca(2+)-activated K(+) channels and Na(+),K(+)-ATPase in prostaglandin E(1)-and E(2)-induced inhibition of the adrenergic response in human vas deferens. Biochem Pharmacol 2011; 82:65-71.
63. Yamamoto M, Share L, Shade RE. Vasopressin release during ventriculo-cisternal perfusion with prostaglandin E2 in the dog. J Endocrinol 1976; 71:325-331.
64. Imanishi M, Kawamura M, Akabane S, Matsushima Y, Kuramochi M, Ito K, Ohta M, Kimura K, Takamiya M, Omae T. Aspirin lowers blood pressure in patients with renovascular hypertension. Hypertension 1989; 14:461-468. (Pubitemid 19270509)
65. Jackson EK, Oates JA, Branch RA. Indomethacin decreases arterial blood pressure and plasma renin activity in rats with aortic ligation. Circ Res 1981; 49:180-185. (Pubitemid 11093193)
66. Bivol LM, Hultström M, Gudbrandsen OA, Berge RK, Iversen BM. Tetradecylthioacetic acid downregulates cyclooxygenase 2 in the renal cortex of two-kidney, one-clip hypertensive rats. Am J Physiol Regul Integr Comp Physiol 2008; 295:R1866-R1873.
67. Yang T, Endo Y, Huang YG, Smart A, Briggs JP, Schnermann J. Renin expression in COX-2-knockout mice on normal or low-salt diets. Am J Physiol Renal Physiol 2000; 279:F819-F825.
68. Ahn KO, Lim SW, Yang HJ, Li C, Sugawara A, Ito S, Choi BS, Kim YS, Kim J, Yang CW. Induction of PPAR gamma mRNA and protein expression by rosiglitazone in chronic cyclosporine nephropathy in the rat. Yonsei Med J 2007; 48:308-316. (Pubitemid 46711764)
69. Cheng HF, Wang JL, Zhang MZ, Wang SW, McKanna JA, Harris RC. Genetic deletion of COX-2 prevents increased renin expression in response to ACE inhibition. Am J Physiol Renal Physiol 2001; 280:F449-F456.
70. Castrop H, Schweda F, Schumacher K, Wolf K, Kurtz A. Role of renocortical cyclooxygenase-2 for renal vascular resistance and macula densa control of renin secretion. J Am Soc Nephrol 2001; 12:867-874. (Pubitemid 32378326)
71. Schnermann J, Briggs JP. Synthesis and secretion of renin in mice with induced genetic mutations. Kidney Int 2012; 81:529-538.
72. Castrop H, Höcherl K, Kurtz A, Schweda F, Todorov V, Wagner C. Physiology of kidney renin. Physiol Rev 2010; 90:607-673.
73. Wang JL, Cheng HF, Harris RC. Cyclooxygenase-2 inhibition decreases renin content and lowers blood pressure in a model of renovascular hypertension. Hypertension 1999; 34:96-101. (Pubitemid 29325725)
74. Richter CM, Godes M, Wagner C, Maser-Gluth C, Herzfeld S, Dorn M, Priem F, Slowinski T, Bauer C, Schneider W, Neumayer HH, Kurtz A, Hocher B. Chronic cyclooxygenase-2 inhibition does not alter blood pressure and kidney function in renovascular hypertensive rats. J Hypertens 2004; 22:191-198. (Pubitemid 38293547)
75. Hockel GM, Cowley AW Jr. Effect of chronic intrarenal prostaglandin E2 infusion and angiotensin II blockade on arterial pressure in the dog. Adv Prostaglandin Thromboxane Res 1980; 7:1061-1065.
76. Câmpean V, Theilig F, Paliege A, Breyer M, Bachmann S. Key enzymes for renal prostaglandin synthesis: site-specific expression in rodent kidney (rat, mouse). Am J Physiol Renal Physiol 2003; 285:F19-F32. (Pubitemid 36818458)
77. Fuson AL, Komlosi P, Unlap TM, Bell PD, Peti-Peterdi J. Immunolocalization of a microsomal prostaglandin E synthase in rabbit kidney. Am J Physiol Renal Physiol 2003; 285:F558-F564. (Pubitemid 37010867)
78. Csukas S, Hanke CJ, Rewolinski D, Campbell WB. Prostaglandin E2-induced aldosterone release is mediated by an EP2 receptor. Hypertension 1998; 31:575-581.
79. Muro S, Tanaka I, Usui T, Kotani M, Koide S, Mukoyama M, Fukata J, Itoh H, Narumiya S, Kawata M, Nakao K. Expression of prostaglandin E receptor EP4 subtype in rat adrenal zona glomerulosa: involvement in aldosterone release. Endocr J 2000; 47:429-436.
80. Breyer MD, Breyer RM. Prostaglandin E receptors and the kidney. Am J Physiol Renal Physiol 2000; 279:F12-F23. (Pubitemid 30619543)
81. Ren J, Karpinski E, Benishin CG. Prostaglandin E2 contracts vascular smooth muscle and inhibits potassium currents in vascular smooth muscle cells of rat tail artery. J Pharmacol Exp Ther 1995; 275:710-719. (Pubitemid 26023616)
82. Bolla M, You D, Loufrani L, Levy BI, Levy-Toledano S, Habib A, Henrion D. Cyclooxygenase involvement in thromboxane-dependent contraction in rat mesenteric resistance arteries. Hypertension 2004; 43:1264-1269. (Pubitemid 38696915)
83. Jadhav V, Jabre A, Lin SZ, Lee TJ. EP1-and EP3-receptors mediate prostaglandin E2-induced constriction of porcine large cerebral arteries. J Cereb Blood Flow Metab 2004; 24:1305-1316. (Pubitemid 40019155)
84. Guan Y, Zhang Y, Wu J, Qi Z, Yang G, Dou D, Gao Y, Chen L, Zhang X, Davis LS, Wei M, Fan X, Carmosino M, Hao C, Imig JD, Breyer RM, Breyer MD. Antihypertensive effects of selective prostaglandin E2 receptor subtype 1 targeting. J Clin Invest 2007; 117:2496-2505. (Pubitemid 47494351)
85. Rutkai I, Feher A, Erdei N, Henrion D, Papp Z, Edes I, Koller A, Kaley G, Bagi Z. Activation of prostaglandin E2 EP1 receptor increases arteriolar tone and blood pressure in mice with type 2 diabetes. Cardiovasc Res 2009; 83:148-154.
86. Suganami T, Mori K, Tanaka I, Mukoyama M, Sugawara A, Makino H, Muro S, Yahata K, Ohuchida S, Maruyama T, Narumiya S, Nakao K. Role of prostaglandin E receptor EP1 subtype in the development of renal injury in genetically hypertensive rats. Hypertension 2003; 42:1183-1190. (Pubitemid 37549075)
87. Hébert RL, Jacobson HR, Breyer MD. Prostaglandin E2 inhibits sodium transport in rabbit cortical collecting duct by increasing intracellular calcium. J Clin Invest 1991; 87:1992-1998.
88. Ariumi H, Takano Y, Masumi A, Takahashi S, Hirabara Y, Honda K, Saito R, Kamiya HO. Roles of the central prostaglandin EP3 receptors in cardiovascular regulation in rats. Neurosci Lett 2002; 324:61-64. (Pubitemid 34442678)
89. Zhang ZH, Yu Y, Wei SG, Nakamura Y, Nakamura K, Felder RB. EP3 receptors mediate PGE2-induced hypothalamic paraventricular nucleus excitation and sympathetic activation. Am J Physiol Heart Circ Physiol 2011; 301:H1559-H1569.
90. Saleem S, Kim YT, Maruyama T, Narumiya S, Doré S. Reduced acute brain injury in PGE2 EP3 receptor-deficient mice after cerebral ischemia. J Neuroimmunol 2009; 208:87-93.
91. Orie NN, Clapp LH. Role of prostanoid IP and EP receptors in mediating vasorelaxant responses to PGI2 analogues in rat tail artery: Evidence for Gi/o modulation via EP3 receptors. Eur J Pharmacol 2011; 654:258-265.
92. Audoly LP, Ruan X, Wagner VA, Goulet JL, Tilley SL, Koller BH, Coffman TM, Arendshorst WJ. Role of EP(2) and EP(3) PGE(2) receptors in control of murine renal hemodynamics. Am J Physiol Heart Circ Physiol 2001; 280:H327-H333.
93. Jones RL, Woodward DF. Interaction of prostanoid EP3 and TP receptors in guinea-pig isolated aorta: contractile self-synergism of 11-deoxy-16,16-dimethyl PGE2. Br J Pharmacol 2011; 162:521-531.
94. Qian YM, Jones RL, Chan KM, Stock AI, Ho JK. Potent contractile actions of prostanoid EP3-receptor agonists on human isolated pulmonary artery. Br J Pharmacol 1994; 113:369-374. (Pubitemid 24310729)
95. Kennedy CR, Zhang Y, Brandon S, Guan Y, Coffee K, Funk CD, Magnuson MA, Oates JA, Breyer MD, Breyer RM. Salt-sensitive hypertension and reduced fertility in mice lacking the prostaglandin EP2 receptor. Nat Med 1999; 5:217-220. (Pubitemid 29068530)
96. Yao B, Xu J, Harris RC, Zhang MZ. Renal localization and regulation of 15-hydroxyprostaglandin dehydrogenase. Am J Physiol Renal Physiol 2008; 294:F433-F439. (Pubitemid 351199409)
97. Nomura T, Chang HY, Lu R, Hankin J, Murphy RC, Schuster VL. Prostaglandin signaling in the renal collecting duct: release, reuptake, and oxidation in the same cell. J Biol Chem 2005; 280:28424-28429. (Pubitemid 41105741)
98. Nomura T, Lu R, Pucci ML, Schuster VL. The two-step model of prostaglandin signal termination: in vitro reconstitution with the prostaglandin transporter and prostaglandin 15 dehydrogenase. Mol Pharmacol 2004; 65:973-978. (Pubitemid 38420503)
99. Uchida S, Nonoguchi H, Endou H. Localization and properties of NAD+-dependent 15-hydroxyprostaglandin dehydrogenase activity in the rat kidney. Pflugers Arch 1985; 404:278-284. (Pubitemid 15070293)
100. Shiraya K, Hirata T, Hatano R, Nagamori S, Wiriyasermkul P, Jutabha P, Matsubara M, Muto S, Tanaka H, Asano S, Anzai N, Endou H, Yamada A, Sakurai H, Kanai Y. A novel transporter of SLC22 family specifically transports prostaglandins and co-localizes with 15-hydroxyprostaglandin dehydrogenase in renal proximal tubules. J Biol Chem 2010; 285:22141-22151.
101. Hatano R, Onoe K, Obara M, Matsubara M, Kanai Y, Muto S, Asano S. Sex hormones induce a gender-related difference in renal expression of a novel prostaglandin transporter, OAT-PG, influencing basal PGE2 concentration. Am J Physiol Renal Physiol 2012; 302:F342-F349.